文章预览
本期胸小星将为大家带来 奥希替尼新辅助治疗Ⅰ-ⅢA期EGFR突变的NSCLC； 未进行PET/CT分期与III期NSCLC患者生存率降低相关 ，一起来看看吧！ 2017·EATTS 01 Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study Collin M. Blakely1,2, Anatoly Urisman2,3, Matthew A. Gubens1,2, Claire K. Mulvey1,2, Greg M. Allen1,2, Stephen C. Shiboski4, Julia K. Rotow5, Turja Chakrabarti1,2, D. Lucas Kerr1,2, Jacqueline V. Aredo1, Bianca Bacaltos2, Megan Gee2, Lisa Tan2, Kirk D. Jones3, W. Patrick Devine3,6, Robert C. Doebele7, Dara L. Aisner8, Tejas Patil7, Erin L. Schenk7, Trever G. Bivona1,2,9, Jonathan W. Riess 10, Melissa Coleman2,11, Johannes R. Kratz2,11, David M. Jablons2,11 1 Department of Medicine, University of California, San Francisco, San Francisco, CA 2 Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Fra
………………………………
